Is Femtech in Asia Becoming Women’s Health Infrastructure?

In July 2026, Philippines telehealth company GoRocky acquired the Kindred brand and related assets from Kindred Health, marking GoRocky’s formal move into women’s health. Importantly, this was an acquisition of selected assets rather than the entire Kindred Health legal entity. The Kindred flagship clinic at Serendra Mall in Bonifacio Global Centre (BGC), Taguig remains open and existing patients continue to receive care.

While a relatively straightforward healthcare transaction, it tells us something much bigger about where the Asian femtech market may be heading in 2026 and beyond. The next phase of regional femtech may not be about building a standalone femtech unicorn, which we have yet to see in Asia. It may be about building the most strategically valuable layer of hybrid women’s healthcare and becoming part of a larger healthcare platform.

Why Kindred?

Founded in the Philippines by Registered Nurse, Jessica de Mesa-Lim, Kindred built a hybrid model combining virtual care with physical clinics, offering consultations, diagnostics, vaccines, ultrasounds and specialist women's healthcare across areas including fertility, menopause and infectious diseases. It had built a meaningful patient base and, importantly, clinical infrastructure. Based on 2024 research by FemTech Association Asia & Milieu Insight, 42% of Filipina women sharing that they primarily learn about women’s health topics through their healthcare professionals, hybrid clinics make sense for consumer accessibility, convenience and budget-options.

Consumer demand for hybrid women’s health with the option for an in-person bricks and mortar experience is growing and an opportunity femtech founders are pursuing. In August 2026 (thanks to our annual tracking and updates by intern Audrina Wong) FemTech Association Asia counts five women’s health clinics in Singapore alone (InSync, HeyTaylor, Osler Health, Orchard Clinic, Prologue Clinic), with Vietnam welcoming The Joyful Nest, a clinic focused on the pregnancy and post-pregnancy journey. Time will tell how these clinics will fund their operations to scale.

As of March 2025, over 70% of investors in Southeast Asia and Hong Kong femtech startups were headquartered or had a SEA regional office, noting ~43% of femtech investors in these markets were based in Singapore. However, Philippines-founded Kindred’s journey demonstrates strong funding support from the local market.

In 2024, Kindred raised a reported US$5.5 million pre-Series A, led by Integra Partners, with participation from Kaya Founders, KSR Ventures, Ava Zobel Pessina, Pawikan Capital Group, TENCO Capital and others. Healthcare-focused venture builder Pulse63 was also closely involved.

These investors were investing in a broader healthcare proposition. Integra Partners was particularly explicit about the thesis when it announced its investment, describing the opportunity as extending well beyond traditional femtech into the ways health conditions manifest differently in women and men.

GoRocky, originally focused on men's health and chronic care, has acquired Kindred's brand and related assets, relying on its evidence that women were an important part of its customer base. More than 60% of its weight-management patients are women. Rather than build a women's-health proposition from scratch, it could acquire an existing brand, clinical capability, patient relationships and infrastructure.

GoRocky isn't simply buying “femtech” to access women’s health, it is buying a capability it needs to build a broader healthcare platform. We have seen a version of this before with Indonesian women’[s health platform, PLans (since rebranded to Ovy Health), acquiring a media and content portion of Ferne Health, one of the early women's-health businesses emerging from Singapore (since closed).

The acquisition of specific functional pillars created by Kindred and Ferne Health are the two examples of femtech M&A in Southeast Asia. Kindred is especially important as it showcases a broader telehealth and chronic-care platform moving into women's health, that femtech is increasingly being viewed not as a niche vertical, but as a missing component of and requirement for growing a healthcare business.

What has Kindred built that another healthcare company would struggle to replicate?

1. A trusted patient relationship

In women's health, trust is an asset.

Among current femtech users, ease of use/convenience (64%) and cost (47%) are the highest determing factors for using femtech products/services. Next at 33% each includes recommendations from healthcare professionals and positive reviews from other end-users/customers. Trust is experts and peers.

Patients don't necessarily want to move between five different apps, clinics and providers for different aspects of their health. A company that has earned that relationship has created something significantly more valuable than a one-off transaction.

2. Clinical infrastructure

Doctors, clinical protocols, diagnostics, physical locations, pharmacy relationships, regulatory knowledge and operational systems are difficult to build. Kindred built its healthcare infrastructure based on consumer needs, then continued to build, improve, adjust and scale the technology to accompany the care.

3. A hybrid model

Digital is essential for access, convenience and scale (especially in a country like the Philippines with over 7,000 islands!) but healthcare is not entirely digital. Kindred's online-to-offline model gives it both a digital relationship and physical clinical capability. Its model also extended into underserved areas through hybrid clinics. This combination can be particularly powerful in fragmented healthcare markets like Southeast Asia.

4. A broader customer journey

A woman who initially enters a platform for contraception, fertility, weight management or a gynaecological consultation may have many healthcare needs over her lifetime. Menstrual health to reproductive health to pregnancy to postpartum care. As patients age, menopause, metabolic health, cardiovascular health, bone health and mental health become increasingly relevant.

The opportunity is not just one product or life stage, rather customer lifetime value built off a lifelong relationship and healthcare journey.

5. Data and Insights

This may ultimately be one of the most valuable assets.

A longitudinal understanding of women's healthcare needs has potential value across clinical care, research, prevention and healthcare innovation. Data that is built from Kindred’s own consumer base in market is a very different proposition from collecting anonymous engagement data on an app.

What larger healthcare market can a femtech company give us access to?

There appears to be an opportunity now is to move from category ownership to healthcare relationship ownership, meaning the building a convenient, easy-to-use, end-to-end, curated, specialised, accessible, hybid healthcare experience that the patient can use across their lifetime healthcare journey.

Kindred illustrates this beautifully.

GoRocky is now talking about expanding the combined proposition across menopause, metabolic health, mental health and sexual health, alongside its existing chronic-care capabilities. That creates a much larger addressable opportunity than a standalone women's-health clinic. It also explains why strategic acquisition can make sense.

Femtech in Southeast Asia is a US$6 billion market and continues to grow.

The Future

We expect more strategic, capabilities transactions as our femtech businesses in Asia continue to mature. This means smaller acquisitions of brands, clinics, technology, patient bases, distribution channels or specialist capabilities.

One example per market of FemTech Association Asia startups to keep your eyes on reflecting this integrated growth model – Hati Health (PH), Pistil (MY), Ovy Health (IN) and Ease (SG).

The future of Asian femtech M&A may be less about one healthcare company buying a femtech company and more about mainstream healthcare companies buying women's-health capabilities.